HiSeq Drives 25 Percent Increase in Illumina's Q3 Revenues | GenomeWeb

Sales of Illumina's HiSeq instrument and consumables are continuing to drive the firm's revenue gains, leading to a 25 percent increase in third quarter revenues over the previous year, the firm said this week.

Illumina reported revenues of $357 million for the three-month period ended Sept. 29, up from $285.9 million for Q3 2012. Its sequencing business grew 37 percent, "driven by impressive demand for consumables and the HiSeq," CEO and President Jay Flatley said during a conference call to discuss the company's third quarter results.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.